Bluestar Genomics Inc.

Based in California, US, and founded in 2016, Bluestar Genomics Inc. operates as a biotechnology company that develops next-generation epigenomic approaches to detect deadly cancers, like pancreatic, early when curative therapies are possible. In May 2021, the company received Series C funding led by current investor Mattias Westman, founding partner of Prosperity Capital Management, with participation from Pathology Asia Holdings Pte Ltd, an independent medical diagnostics group in Southeast Asia, as well as a venture fund based in San Francisco, CA, and a large, diversified asset manager on the west coast, among others. Bluestar Genomics Inc.

combines novel epigenomic technology with machine learning to detect early pancreatic cancer from a standard blood draw by analyzing cell-free DNA in plasma, these can be used as new biomarkers that can detect pancreatic cancer before the malignancy. Bluestar Genomics Inc. plans to conduct a large clinical validation study to confirm the assay’s ability to detect pancreatic cancer in patients with new-onset diabetes.